Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 1, 2015, Pages 32-37

  Louter, Maartje ^a,b   Maetzler, Walter ^c   Prinzen, Jos ^d   Van Lummel, Rob C ^d   Hobert, Markus ^c   Arends, Johan B A M ^b,e   Bloem, Bastiaan R ^a   Streffer, Johannes ^f   Berg, Daniela ^c   Overeem, Sebastiaan ^a,b   Liepelt Scarfone, Inga ^c  

^a RADBOUD UNIVERSITY   (Netherlands)

^b EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d McRoberts BV   (Netherlands)

^e EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACCELEROMETER; ADULT; AGED; ARTICLE; BODY MOVEMENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; OLFACTORY TRACT; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRODROMAL SYMPTOM; QUANTITATIVE ANALYSIS; SENSORY DYSFUNCTION; SUBSTANTIA NIGRA; VELOCITY; ACCELEROMETRY; CASE CONTROL STUDY; COMPLICATION; EARLY DIAGNOSIS; MIDDLE AGED; MOVEMENT (PHYSIOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP; SMELLING DISORDER; VERY ELDERLY;

BIOLOGICAL MARKER;

ACCELEROMETRY; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT; OLFACTION DISORDERS; PARKINSON DISEASE; PRODROMAL SYMPTOMS; SLEEP; SUBSTANTIA NIGRA;

EID: 84919779901     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-306851     Document Type: Article

References (41)

1. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson' s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
2. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-301.
3. Gaenslen A, Swid I, Liepelt-Scarfone I, et al. The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. Mov Disord 2011;26:653-8.
4. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-82.
5. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119(Pt 2):585-91.
6. Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the preclinical period of Parkinson 's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-19.
7. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001;16:41-6.
8. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson' s disease. Ann Neurol 2008;63:167-73.
9. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996;46:388-93.
10. Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572-7.
11. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-300.
12. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012;27:617-26.
13. Ross GW, Abbott RD, Petrovitch H, et al. Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord 2012;18 (Suppl 1):S199-202.
14. Maetzler W, Mancini M, Liepelt-Scarfone I, et al. Impaired trunk stability in individuals at high risk for Parkinson's disease. PLoS ONE 2012;7:e32240.
15. de Lau LM, Koudstaal PJ, Hofman A, et al. Subjective complaints precede Parkinson disease: the rotterdam study. Arch Neurol 2006;63:362-5.
16. Gao X, Chen H, Schwarzschild MA, et al. Perceived imbalance and risk of Parkinson' s disease. Mov Disord 2008;23:613-16.
17. Maetzler W, Hausdorff JM. Motor signs in the prodromal phase of Parkinson's disease. Mov Disord 2012;27:627-33.
18. Berg D, Jabs B, Merschdorf U, et al. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 2001;50:463-7.
19. Berg D, Behnke S, Seppi K, et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 2013;28(2):216-19.
20. Walter U, Behnke S, Eyding J, et al . Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound in medicine & biology 2007;33:15-25.
21. Berg D, Marek K, Ross GW, et al. Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord 2012;27:656-65.
22. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 2011;68:932-7.
23. van Hilten B, Hoff JI, Middelkoop HA, et al . Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. Arch Neurol 1994; 51:922-8.
24. Nass A, Nass RD. Actigraphic evidence for night-time hyperkinesia in Parkinson's disease. Int J Neurosci 2008;118:291-310.
25. Laihinen A, Alihanka J, Raitasuo S, et al. Sleep movements and associated autonomic nervous activities in patients with Parkinson's disease. Acta Neurol Scand 1987;76:64-8.
26. Liepelt-Scarfone I, Gauss K, Maetzler W, et al. Evaluation of progression markers in the premotor phase of Parkinson 's disease-the PMPP study. Neuroepidemiology 2013;41:174-82.
27. Liepelt I, Behnke S, Schweitzer K, et al. Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging 2011;32:1599-606.
28. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
29. Hummel T, Konnerth CG, Rosenheim K, et al. Screening of olfactory function with a four-minute odor identi fication test: reliability, normative data, and investigations in patients with olfactory loss. Ann Otol Rhinol Laryngol 2001;110:976-81.
30. Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 1996;47:155-60.
31. Berg D, Seppi K, Liepelt I, et al. Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord 2010; 25:1464-9.
32. Hughes AJ, Daniel SE, Lees AJ. The clinical features of Parkinson's disease in 100 histologically proven cases. Adv.Neurol 1993;60:595-9.
33. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25: 2649-53.
34. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
35. Stiasny-Kolster K, Mayer G, Schafer S, et al. The REM sleep behavior disorder screening questionnaire - a new diagnostic instrument. Mov Disord 2007;22:2386-93.
36. Peralta CM, Frauscher B, Seppi K, et al. Restless legs syndrome in Parkinson's disease. Mov Disord 2009;24:2076-80.
37. Bossenbroek L, Kosse N, Ten Hacken N, et al. Validation of the DynaPort MiniMod during sleep: a pilot study. Percept Mot Skills 2010;111:936-46.
38. Mirelman A, Gurevich T, Giladi N, et al. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011;69:193-7.
39. Hausdorff JM. Gait variability: methods, modeling and meaning. J Neuroeng Rehabilitation 2005;2:19.
40. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005;65:1442-6.
41. van Schooten KS, Rispens SM, Elders PJ, et al. Assessing Physical Activity in Older Adults: Required Days of Trunk Accelerometer Measurements for Reliable Estimation. J Aging Phys Act 2013.